VERMOX
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERMOX is an oral chewable tablet small-molecule anthelmintic approved in 1974 by Johnson & Johnson. The drug treats parasitic worm infections through its mechanism of action against intestinal nematodes. It remains a standard-of-care option for helminthic diseases in both developed and resource-limited settings.
LOE Approaching
With LOE approaching and 30% competitive pressure, this mature franchise likely operates with a lean, efficiency-focused team managing decline and generic transition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and a legacy product approaching LOE, VERMOX offers limited growth opportunities for career advancement. Roles on this franchise typically focus on defending market share, managing generic transition, and optimizing operations rather than innovation or expansion.
Product ManagerField Sales
Worked on VERMOX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.